Last July, Sen. Claire McCaskill (D-Mo.) asked several drug makers and wholesalers to provide various forms of information about the steps they have taken to mitigate the opioid epidemic. But one company, Teva Pharmaceuticals (TEVA), is “stonewalling,” as far as she is concerned.

Instead of turning over documents about monitoring suspicious orders — a key focus of her investigation — Teva responded with two brief letters describing those efforts. And in a second letter sent in October, Teva attorneys maintained the drug maker has been willing to discuss, “at a general level,” the information requested, but acknowledged the company “declined to produce the documents.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • They have been waffling and withholding information for 20 years. No one one wants to look at the obscene profits, the last 20 years of weaponized drug marketing or the industries that are still profiting from misinformation, death and despair. No one wants to look at the Facts. They used this Epidemic of Despair, to hide the death Rates. They are currently using it to obscure the number of adverse events, failed surgeries and injured workers. It was a cost benefit analysis, meant to help all of the health related industries increase their profitability. At the same time they chose to ignore every other social problem. Pharma and their media and industry friends are still misleading the public. Since 2000 they have found that bought off politicians, cherry picked numbers, lies and industry insiders can easily distract people from the Facts. Their lawyers will probably argue that all of that information is proprietary anyway.

  • A question for our scribe – how much, if any, of TEVA’s opioid business arrived with the purchase of Allergan’s (nee Watson etc) generics business? One might wonder if that is the case, whether they even really know the answer / have the numbers?
    Could this be another case of the curse of a legacy business? This Observer (“079”) knoweth not and defers to the sage of Pharmalot.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy